Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Xavier Thomas; Emmanuel Raffoux; Aline Renneville; Cécile Pautas; Stéphane de Botton; Thierry de Revel; Oumedaly Reman; Christine Terré; Claude Gardin; Youcef Chelghoum; Nicolas Boissel; Bruno Quesnel; Catherine Cordonnier; Jean Henri Bourhis; Mohamed Elhamri; Pierre Fenaux; Claude Preudhomme; Gérard Socié; Mauricette Michallet; Sylvie Castaigne; Hervé Dombret

doi:10.1016/j.leukres.2012.04.020

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Xavier Thomas, Emmanuel Raffoux, Aline Renneville, Cécile Pautas, Stéphane de Botton, Thierry de Revel, Oumedaly Reman, Christine Terré, Claude Gardin, Youcef Chelghoum, Nicolas Boissel, Bruno Quesnel, Catherine Cordonnier, Jean Henri Bourhis, Mohamed Elhamri, Pierre Fenaux, Claude Preudhomme, Gérard Socié, Mauricette Michallet, Sylvie CastaigneHervé Dombret

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Forty-seven percent of adults with acute myeloid leukemia (AML) who entered the ALFA-9802 trial and achieved a first complete remission (CR) experienced a first relapse. We examined the outcome of these 190 adult patients. Eighty-four patients (44%) achieved a second CR. The median overall survival (OS) after relapse was 8.9. months with a 2-year OS at 25%. Factors predicting a better outcome after relapse were stem cell transplant (SCT) performed in second CR and a first CR duration >1. year. Risk groups defined at the time of diagnosis and treatment received in first CR also influenced the outcome after relapse. The best results were obtained in patients with core binding factor (CBF)-AML, while patients initially defined as favorable intermediate risk showed a similar outcome after relapse than those initially entering the poor risk group. We conclude that most adult patients with recurring AML could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option at this stage of the disease.

Original language	English
Pages (from-to)	1112-1118
Number of pages	7
Journal	Leukemia Research
Volume	36
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2012.04.020
Publication status	Published - 1 Sept 2012

Keywords

Acute myeloid leukemia
Allogeneic transplantation
Chemotherapy
Prognosis
Relapse

Access to Document

10.1016/j.leukres.2012.04.020

Cite this

Thomas, X., Raffoux, E., Renneville, A., Pautas, C., de Botton, S., de Revel, T., Reman, O., Terré, C., Gardin, C., Chelghoum, Y., Boissel, N., Quesnel, B., Cordonnier, C., Bourhis, J. H., Elhamri, M., Fenaux, P., Preudhomme, C., Socié, G., Michallet, M., ... Dombret, H. (2012). Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leukemia Research, 36(9), 1112-1118. https://doi.org/10.1016/j.leukres.2012.04.020

@article{063f0852371d44a1b6acf1d26c66614f,

title = "Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial",

abstract = "Forty-seven percent of adults with acute myeloid leukemia (AML) who entered the ALFA-9802 trial and achieved a first complete remission (CR) experienced a first relapse. We examined the outcome of these 190 adult patients. Eighty-four patients (44%) achieved a second CR. The median overall survival (OS) after relapse was 8.9. months with a 2-year OS at 25%. Factors predicting a better outcome after relapse were stem cell transplant (SCT) performed in second CR and a first CR duration >1. year. Risk groups defined at the time of diagnosis and treatment received in first CR also influenced the outcome after relapse. The best results were obtained in patients with core binding factor (CBF)-AML, while patients initially defined as favorable intermediate risk showed a similar outcome after relapse than those initially entering the poor risk group. We conclude that most adult patients with recurring AML could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option at this stage of the disease.",

keywords = "Acute myeloid leukemia, Allogeneic transplantation, Chemotherapy, Prognosis, Relapse",

author = "Xavier Thomas and Emmanuel Raffoux and Aline Renneville and C{\'e}cile Pautas and {de Botton}, St{\'e}phane and {de Revel}, Thierry and Oumedaly Reman and Christine Terr{\'e} and Claude Gardin and Youcef Chelghoum and Nicolas Boissel and Bruno Quesnel and Catherine Cordonnier and Bourhis, {Jean Henri} and Mohamed Elhamri and Pierre Fenaux and Claude Preudhomme and G{\'e}rard Soci{\'e} and Mauricette Michallet and Sylvie Castaigne and Herv{\'e} Dombret",

year = "2012",

month = sep,

day = "1",

doi = "10.1016/j.leukres.2012.04.020",

language = "English",

volume = "36",

pages = "1112--1118",

journal = "Leukemia Research",

issn = "0145-2126",

number = "9",

}

Thomas, X, Raffoux, E, Renneville, A, Pautas, C, de Botton, S, de Revel, T, Reman, O, Terré, C, Gardin, C, Chelghoum, Y, Boissel, N, Quesnel, B, Cordonnier, C, Bourhis, JH, Elhamri, M, Fenaux, P, Preudhomme, C, Socié, G, Michallet, M, Castaigne, S & Dombret, H 2012, 'Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial', Leukemia Research, vol. 36, no. 9, pp. 1112-1118. https://doi.org/10.1016/j.leukres.2012.04.020

TY - JOUR

T1 - Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

AU - Thomas, Xavier

AU - Raffoux, Emmanuel

AU - Renneville, Aline

AU - Pautas, Cécile

AU - de Botton, Stéphane

AU - de Revel, Thierry

AU - Reman, Oumedaly

AU - Terré, Christine

AU - Gardin, Claude

AU - Chelghoum, Youcef

AU - Boissel, Nicolas

AU - Quesnel, Bruno

AU - Cordonnier, Catherine

AU - Bourhis, Jean Henri

AU - Elhamri, Mohamed

AU - Fenaux, Pierre

AU - Preudhomme, Claude

AU - Socié, Gérard

AU - Michallet, Mauricette

AU - Castaigne, Sylvie

AU - Dombret, Hervé

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Forty-seven percent of adults with acute myeloid leukemia (AML) who entered the ALFA-9802 trial and achieved a first complete remission (CR) experienced a first relapse. We examined the outcome of these 190 adult patients. Eighty-four patients (44%) achieved a second CR. The median overall survival (OS) after relapse was 8.9. months with a 2-year OS at 25%. Factors predicting a better outcome after relapse were stem cell transplant (SCT) performed in second CR and a first CR duration >1. year. Risk groups defined at the time of diagnosis and treatment received in first CR also influenced the outcome after relapse. The best results were obtained in patients with core binding factor (CBF)-AML, while patients initially defined as favorable intermediate risk showed a similar outcome after relapse than those initially entering the poor risk group. We conclude that most adult patients with recurring AML could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option at this stage of the disease.

AB - Forty-seven percent of adults with acute myeloid leukemia (AML) who entered the ALFA-9802 trial and achieved a first complete remission (CR) experienced a first relapse. We examined the outcome of these 190 adult patients. Eighty-four patients (44%) achieved a second CR. The median overall survival (OS) after relapse was 8.9. months with a 2-year OS at 25%. Factors predicting a better outcome after relapse were stem cell transplant (SCT) performed in second CR and a first CR duration >1. year. Risk groups defined at the time of diagnosis and treatment received in first CR also influenced the outcome after relapse. The best results were obtained in patients with core binding factor (CBF)-AML, while patients initially defined as favorable intermediate risk showed a similar outcome after relapse than those initially entering the poor risk group. We conclude that most adult patients with recurring AML could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option at this stage of the disease.

KW - Acute myeloid leukemia

KW - Allogeneic transplantation

KW - Chemotherapy

KW - Prognosis

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84864006671&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.04.020

DO - 10.1016/j.leukres.2012.04.020

M3 - Article

C2 - 22647869

AN - SCOPUS:84864006671

SN - 0145-2126

VL - 36

SP - 1112

EP - 1118

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Abstract

Keywords

Access to Document

Other files and links

Cite this